Mayo Clinic, GE Healthcare Partner on Medical Imaging, Theranostics Advancement

Mayo Clinic and GE Healthcare today announced a strategic collaboration for research and product development programs to better the experience of patients and medical professionals in radiology and the delivery of novel therapies. The companies said they seek to “better equip clinicians with technology to precisely diagnose and treat medical conditions and personalize the patient experience at each step of their care journey through the clinical translation of novel technologies and approaches to medical imaging and theranostics.” The collaboration will be comprised of Mayo Clinic and GE scientists, technology developers, clinicians, and other healthcare professionals.

The Strategic Collaboration for Innovation in Medical Imaging and Theranostics will focus on four core areas, including the rapid acceleration of the development and clinical translation of advanced Magnetic Resonance technologies and techniques through AI enabled exams, and the integration of precise imaging and dosimetry of highly targeted theranostic agents, enabling broader access and more efficient radioisotope production. Additionally, the collaboration intends to make diagnostic and interventional ultrasound easier and faster to use and read while also advancing automation and quantification to improve consistency or care, clinician experience, and patient access. Lastly, they want to leverage multi-modal data, AI, and digital health platforms to streamline clinical operations and support more personalized diagnosis and therapy.

“We are at a critical time in healthcare — technology is rapidly evolving, and we have a responsibility to drive healthcare capabilities through clinical translation and adoption of advanced technologies,” said Matthew Callstrom, MD, PhD, chair of radiology at Mayo Clinic, in a press release announcing the collaboration. “This collaboration brings our research and clinical teams’ expertise and feedback closer to product development and commercialization of innovation, ultimately accelerating the rate of translation of our research to patient care and offering greater opportunity for global impact.”